Rasagiline NDC 13668-446

NDC codes

FDA NDC Directory

Product NDC (as listed)13668-446Labeler and product segments. Claims need a package NDC.

Product NDC at billing width13668-0446Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
13668-446-05	13668044605	500 TABLET in 1 CONTAINER (13668-446-05)Marketed from Nov 15, 2025
13668-446-30	13668044630	30 TABLET in 1 CONTAINER (13668-446-30)Marketed from Nov 15, 2025
13668-446-90	13668044690	90 TABLET in 1 CONTAINER (13668-446-90)Marketed from Nov 15, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Rasagiline
Generic name (nonproprietary): rasagiline
Active ingredients: Rasagiline mesylate — 1 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Torrent Pharmaceuticals Limited
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 210150
Marketing start: Nov 15, 2025
Listing expires: Dec 31, 2027
Other FDA classes: Monoamine Oxidase Inhibitors (Mechanism)
Identifiers: Product ID 13668-446_fa1b2a7e-f459-4432-97f2-23d2c07c2dacSPL ID fa1b2a7e-f459-4432-97f2-23d2c07c2dacSPL set ID 2c5e3cde-1158-4b5a-9a2b-ea6c987a65e4RxCUI 608328, 636664UNII LH8C2JI290
Pharmacologic class: Monoamine Oxidase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N413668044605 followed by a unit qualifier and the quantity

Package 13668-0446-05. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 11, 2026.

Indications (excerpt from the label)

Rasagiline tablets are indicated for the treatment of Parkinson's disease (PD). Rasagiline Tablets, a monoamine oxidase (MAO)-B inhibitor (MAOI), is indicated for the treatment of Parkinson's disease ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 210150

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 210150
Product	Strength	Form · route	Labeler	Product NDC
Rasagiline	Rasagiline mesylate .5 mg/1	TabletOral	Torrent Pharmaceuticals Limited	13668-447